Sean: Perhaps because Michelle Kilcoyne left CYDY
Post# of 151893
A plausible answer to the above question would jibe Respert's analysis that CYDY management would much prefer to avoid the time and expense of building out a go it alone in-house drug development structure in favor of having a BP partnership/eventual BO doing that heavy lifting. In that vein, the fact that these 2 jobs remain open is consistent with the premise that an oncology partnership is on the near horizon.

